Vaidyanathan Subramaniam,  —

Recent Posts

• Researchers to study FXTAS risk in people with FMR1 premutation
• Mirum plans 2025 Phase 2 trial testing fragile X treatment
• New company Aptadir to develop gene reactivating therapy for fragile X
• FRAXA, Marvel Biosciences team up to test therapy in fragile X animal models
• Protocols for US trials of zatolmilast amended to increase accessibility
• Several initiatives on tap for Fragile X Awareness Month in July
• Education, empowerment aim of International Fragile X Conference
• FDA clears Phase 2 trial of oral SPG601 in men with fragile X
• LivJoy Foundation funds research in understudied female fragile X population
• Two-med combo normalized behavior, improved memory in fragile X mice